Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 1/20 | 0.53 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | PPARA | Q07869 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | TAS1R3 | Q7RTX0 | 4/20 | 0.47 |
| ▸ | TAS1R1 | Q7RTX1 | 4/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | APLNR | P35414 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2733675 | 0.91 | DHFR (0.50) | DHFRKDM4CTP53LMNAKMT2A | |
| SCHEMBL209125 | 0.83 | TP53 (0.56) | TP53KMT2AMEN1 | |
| SCHEMBL5583428 | 0.82 | HIF1A (0.58) | TP53LMNAPPARAKMT2AMEN1 | |
| SCHEMBL3558423 | 0.81 | TUBB4A (0.54) | DHFRTP53LMNAKMT2AMEN1 | |
| SCHEMBL3560484 | 0.79 | LMNA (0.56) | DHFRTP53LMNAKMT2AMEN1 | |
| SCHEMBL29527237 | 0.78 | KDM4E (0.66) | TP53LMNATAS1R3TAS1R1CA1 | |
| SCHEMBL335319 | 0.78 | KDM4E (0.66) | TP53LMNATAS1R3TAS1R1CA1 | |
| SCHEMBL21639656 | 0.78 | CA1 (0.72) | DHFRKDM4CPPARAKMT2AMEN1 | |
| Methylene Chloride SCHEMBL28849518 | 0.77 | LMNA (0.62) | TP53LMNAKMT2ATAS1R3TAS1R1 | |
| Hydrochloric Acid SCHEMBL11498190 | 0.77 | KDM4E (0.64) | TP53LMNATAS1R3TAS1R1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070213330-A1 | Anticancer agents; antiproliferative agents | METHYLGENE INC. (CA) | 2007-09-13 | — | — | US | disclosed |
| US-7253204-B2 | Antiproliferative agents | METHYLGENE INC. (CA) | 2007-08-07 | — | — | US | disclosed |
| EP-1735319-A1 | INHIBITORS OF HISTONE DEACETYLASE | Methylgene, Inc. (CA) | 2006-12-27 | — | — | EP | disclosed |
| US-20050245518-A1 | Antiproliferative agents | METHYLGENE, INC. | 2005-11-03 | — | — | US | disclosed |
| WO-2005092899-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2005-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213330-A1 | Anticancer agents; antiproliferative agents | HDAC1, HDAC11, HDAC5 | DHFR 460/4885KDM4C 180/4885TP53 86/4885 |
| US-20050245518-A1 | Antiproliferative agents | HDAC1, HDAC11, HDAC5 | DHFR 386/4885KDM4C 187/4885TP53 115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.